41727-48-4

Basic information

• Product Name: METHYL 4-AMINO-3,5-DICHLOROBENZOATE
• Synonyms: METHYL 4-AMINO-3,5-DICHLOROBENZOATE;4-Amino-3,5-dichlorobenzoic acid methyl ester
• CAS NO: 41727-48-4
• Molecular Formula: C₈H₇Cl₂NO₂
• Molecular Weight: 220.05
• Mol File: 41727-48-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 79-81
• Boiling Point: 342 °C at 760 mmHg
• Flash Point: 160.6 °C
• Appearance: /
• Density: 1.433 g/cm³
• Vapor Pressure: 7.77E-05mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: METHYL 4-AMINO-3,5-DICHLOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-AMINO-3,5-DICHLOROBENZOATE(41727-48-4)
• EPA Substance Registry System: METHYL 4-AMINO-3,5-DICHLOROBENZOATE(41727-48-4)

Safety Data

• Hazardous Substances Data: 41727-48-4(Hazardous Substances Data)

Usage

General Description

Methyl 4-amino-3,5-dichlorobenzoate is a chemical compound with the molecular formula C8H7Cl2NO2. It is a dicarboxylic acid ester with two chlorine atoms and an amino group attached to a benzene ring. METHYL 4-AMINO-3,5-DICHLOROBENZOATE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential antifungal and antibacterial properties. Additionally, it is used in the production of dyes, pigments, and other fine chemicals. Methyl 4-amino-3,5-dichlorobenzoate should be handled and stored according to standard safety procedures and guidelines due to its potential hazardous nature.

InChI:InChI=1/C8H7Cl2NO2/c1-13-8(12)4-2-5(9)7(11)6(10)3-4/h2-3H,11H2,1H3

Upstream product

• 67-56-1 methanol 
• 56961-25-2 4-amino-3,5-dichlorobenzoic acid 
• 150-13-0 4-amino-benzoic acid 
• 98557-39-2 1,2,3,3,5,5,6-heptachloro-4-chloroimino-cyclohexanecarboxylic acid methyl ester 
• 186581-53-3 diazomethane 
• 619-45-4 4-methoxycarbonyl aniline 
• 7664-93-9 sulfuric acid 

Downstream Products

• 51928-44-0 4-Butylamino-3,5-dichloro-benzoic acid methyl ester 
• 444664-49-7 C₉H₅Cl₂NO₃ 
• 651059-00-6 methyl 3,5-dichloro-4-cyanobenzoate 
• 608-31-1 2,6-Dichloroaniline 
• 117738-81-5 methyl 4-bromo-3,5-dichlorobenzoate 
• 120077-80-7 4-bromo-3,5-dichlorobenzaldehyde 
• 98557-37-0 1,2,3,3,5,5,6-heptachloro-4-oxo-cyclohexanecarboxylic acid methyl ester 
• 1416420-00-2 3,5-dichloro-N-(4-chlorophenyl)-4-(2,3,5-trichloro-4,6-dicyanophenylamino)benzamide 
• 1416419-99-2 C₂₁H₉Cl₅N₄O 
• 1416422-30-4 3,5-dichloro-4-(2,3,5-trichloro-4,6-dicyanophenylamino)benzoyl chloride 
• 1416420-02-4 C₁₅H₄Cl₅N₃O₂ 
• 1416419-98-1 C₁₆H₆Cl₅N₃O₂ 
• 74878-32-3 4-amino-3,5-dichlorobenzyl alcohol 
• 51928-73-5 (E)-3-(4-Butylamino-3,5-dichloro-phenyl)-N-cyclopropyl-acrylamide 

Relevant articles and documents

HERBICIDAL SUBSTITUTED 3-PHENYL-4-FLUOROBENZOYL PYRAZOLES

Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein X1, X2, X3, n and P are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME

The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

Pharmacologically active CNS compound

The invention provides a series of compounds of formula (I) and salts thereof, wherein for example,R1 and R2, which may be the same or different each represent -NR13R14 where R13 and R14 may each independently represent hydrogen or alkyl or, taken together with the nitrogen atom to which they are attached form a heterocyclic ring, optionally substituted by one or more alkyl or arylalkyl groups and optionally containing a further heteroatom;, R3 is hydrogen, haloalkyl, alkoxymethyl or alkyl;, R4 is hydrogen, nitro or halo;, R5 is hydrogen or halo;, R6 is hydrogen, halo, nitro, amino, alkylamino or dialkylamino;, R7 is hydrogen or halo;, R8 is hydrogen or halo; The compounds may be used for the treatment or prophylaxis of a neurodegenerative or other neurological disorder of the CNS, the aetiology or which includes excessive release of the neurotransmitter glutamate.